HTT and Huntington disease: Importantly, chronic treatment with T1-11 markedly reduced the formation of striatal Htt aggregates, a hallmark of HD, as assessed by filtered retardation assays (Fig. 6B) and immunofluorescence analyses (Fig. 6C).